Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1

Background Low-grade gliomas (LGGs) occurring in children can result in many different neurologic complications, including seizures. MEK inhibitors are increasingly being used to treat LGG, but their effect on associated neurologic symptoms has not been established. Results Here, we report a patient...

Full description

Saved in:
Bibliographic Details
Published inChild's nervous system Vol. 38; no. 11; pp. 2245 - 2249
Main Authors Cantor, Evan, Meyer, Ashley, Morris, Stephanie M., Weisenberg, Judith L. Z., Brossier, Nicole M.
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.11.2022
Subjects
Case Report
Medicine
Medicine & Public Health
Neurosciences
Neurosurgery
NF1
Seizure
MEK inhibitor
Selumetinib
Epilepsy
Neurofibromatosis
Online AccessGet full text

Cover

More Information
Summary:Background Low-grade gliomas (LGGs) occurring in children can result in many different neurologic complications, including seizures. MEK inhibitors are increasingly being used to treat LGG, but their effect on associated neurologic symptoms has not been established. Results Here, we report a patient with neurofibromatosis type 1 (NF1), medically refractory epilepsy (MRE), and an extensive optic pathway glioma (OPG) who developed dose-dependent seizure control while being treated with selumetinib. Seizure frequency rebounded after dose reduction for cardiac toxicity, then improved, and finally ceased after restarting full dosing, allowing confidence in the cause of improvement. Conclusion Selumetinib may have promise in epilepsy management in other children with NF1 or LGG.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0256-7040
1433-0350
DOI:10.1007/s00381-022-05571-y